Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney

Toxicology

Volumn 310, Issue , 2013, Pages 115-123

  Domitrović, Robert ^a   Cvijanović, Olga ^a   Pugel, Ester Pernjak ^a   Zagorac, Gordana Blagojević ^a   Mahmutefendić, Hana ^a   Škoda, Marko ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Apoptosis; Cisplatin nephrotoxicity; Inflammation; Luteolin; Oxidative nitrosative stress

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; CASPASE 3; CISPLATIN; CREATININE; CYCLOOXYGENASE 2; CYTOCHROME P450 2E1; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUTEOLIN; PLATINUM; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; MALE; MOUSE; NEPHRITIS; NEPHROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

APOPTOSIS; CISPLATIN NEPHROTOXICITY; INFLAMMATION; LUTEOLIN; OXIDATIVE/NITROSATIVE STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LUTEOLIN; MALE; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; PLATINUM;

EID: 84881000960     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.05.015     Document Type: Article

References (46)

1. Alchin K.F. Ototoxicity in Patients Receiving Concurrent Cisplatin and Cranial Irradiation Therapy for the Treatment of Head and Neck Cancers: An Audiometric Follow-up 2010, Department of Communication Disorders. University of Canterbury, Christchurch, New Zealand, (Ph. D. Dissertation).
2. Aleksunes L.M., Augustine L.M., Scheffer G.L., et al. Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology 2008, 250:82-88.
3. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 1985, 113:548-555.
4. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23:460-464.
5. Arjumand W., Sultana S. Glycyrrhizic acid, a phytochemical with a protective role against cisplatin-induced genotoxicity and nephrotoxicity. Life Sci. 2011, 89:422-429.
6. Ashokkumar P., Sudhandiran G. Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest. New Drugs 2011, 29:273-284.
7. Bischin C., Lupan A., Taciuc V., et al. Interactions between proteins and platinum-containing anti-cancer drugs. Mini Rev. Med. Chem. 2011, 11:214-224.
8. Boatright K.M., Salvesen G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 2003, 15:725-731.
9. Borst P., Evers R., Kool M., et al. A family of drug transporters, the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92:1295-1302.
10. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 1976:248-254.
11. Bragado P., Armesilla A., Silva A., et al. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007, 12:1733-1742.
12. Brozović A., Ambriović-Ristov A., Osmak M. The relationship between cisplatin-induced reactive oxygen species glutathione and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol. 2010, 40:347-359.
13. Chen C., Slitt A.L., Dieter M.Z., et al. Up-regulation of Mrp4 expression in kidney of Mrp2-deficient TR-rats. Biochem. Pharmacol. 2005, 70:1088-1095.
14. Domitrović R., Jakovac H., Milin Č., et al. Dose- and time-dependent effects of luteolin on carbon tetrachloride-induced hepatotoxicity in mice. Exp. Toxicol. Pathol. 2009, 61:581-589.
15. Domitrović R., Jakovac H., Tomac J., et al. Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. Toxicol. Appl. Pharmacol. 2009, 241:311-321.
16. Domitrović R., Jakovac H., Marchesi V.V., et al. Preventive and therapeutic effects of oleuropein against carbon tetrachloride-induced liver damage in mice. Pharmacol. Res. 2012, 65:451-464.
17. Fu J., Chen D., Zhao B., et al. Luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress constitutive activation of STAT3. PLoS ONE 2012, 7:e49194.
18. Jiang M., Yi X., Hsu S., et al. Role of p53 in cisplatin-induced tubular cell apoptosis, dependence on p53 transcriptional activity. Am. J. Physiol. Renal Physiol. 2004, 287:F1140-F1147.
19. Kang K.P., Park S.K., Kim D.H., et al. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrol. Dial. Transplant 2011, 26:814-822.
20. Kim D.H., Jung Y.J., Lee J.E., et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am. J. Physiol. Renal Physiol. 2011, 301:F427-F435.
21. König J., Nies A.T., Cui Y., et al. Conjugate export pumps of the multidrug resistance protein (MRP) family, localization substrate specificity and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1999, 11461:377-394.
22. Kris M.G., Gralla R.J., Tyson L.B., et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J. Clin. Oncol. 1989, 7:108-114.
23. Kumar S., Sharma R., Roychowdhury A. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective. Curr. Med. Chem. 2012, 19:3605-3621.
24. Lee S., Kim W., Moon S.O., et al. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol. Dial. Transplant 2006, 21:2096-2105.
25. Lee K.W., Jeong J.Y., Lim B.J., et al. Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 2009, 257:137-143.
26. Lee E.J., Oh S.Y., Sung M.K. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem. Toxicol. 2012, 50:4136-4143.
27. Leemans J.C., Stokman G., Claessen N., et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 2005, 115:2894-2903.
28. Liu H., Baliga R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63:1687-1696.
29. López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 2009, 9:31-59.
30. Mukhopadhyay P., Horváth B., Kechrid M., et al. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic. Biol. Med. 2011, 51:1774-1788.
31. Munić V., Kelnerić Z., Mikac L., et al. Differences in assessment of macrolide interaction with human MDR1 (ABCB1 P-gp) using rhodamine-123 efflux ATPase activity and cellular accumulation assays. Eur. J. Pharm. Sci. 2010, 41:86-95.
32. Munić V., Hlevnjak M., Eraković Haber V. Characterization of rhodamine-123 calcein and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur. J. Pharm. Sci. 2011, 43:359-369.
33. Olver I., Paska W., Depierre A., et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann. Oncol. 1996, 7:945-952.
34. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87:315-424.
35. Pan H., Mukhopadhyay P., Rajesh M., et al. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress inflammation and cell death. J. Pharmacol. Exp. Ther. 2009, 328:708-714.
36. Ramesh G., Reeves W.B. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002, 110:835-842.
37. Sahin K., Tuzcu M., Gencoglu H., et al. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sci 2010, 87:240-245.
38. Shi R., Huang Q., Zhu X., et al. Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol. Cancer Ther. 2007, 6:1338-1347.
39. Srivastava R.C., Farookh A., Ahmad N., et al. Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats. Biometals 1996, 9:139-142.
40. Tak P.P., Firestein G.S. NF-κB, a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
41. Verbanac D., Milin Č., Domitrović R., et al. Determination of standard zinc values in the intact tissues of mice by ICP spectrometry. Biol.Trace Elem. Res. 1997, 57:91-96.
42. Vousden K.H., Lu X. Live or let die, the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
43. Wu C.P., Calcagno A.M., Hladky S.B., et al. Modulatory effects of plant phenols on human multidrug-resistance proteins 1 4 and 5 (ABCC1 4 and 5). FEBS J. 2005, 272:4725-4740.
44. Wu C.T., Sheu M.L., Tsai K.S., et al. Salubrinal, an eIF2α dephosphorylation inhibitor, enhances cisplatin-induced oxidative stress and nephrotoxicity in a mouse model. Free Radic. Biol. Med. 2011, 51:671-680.
45. Yan J., Wang Q., Zheng X., et al. Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem. Biophys. Res. Commun. 2012, 417:842-846.
46. Yao X., Panichpisal K., Kurtzman N., et al. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.